Clinical Trial Update: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating amifampridine phosphate for Lambert-Eaton Myasthenic Syndrome has been completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lambert-eaton Myasthenic Syndrome

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Lambert-Eaton Myasthenic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-12-24